| Code | CSB-RA008531MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to JJP-1212, designed for research targeting FCAR (Fc fragment of IgA receptor), also known as CD89. FCAR is an immunoglobulin superfamily receptor expressed primarily on myeloid cells including neutrophils, monocytes, macrophages, and eosinophils. This receptor mediates critical immune functions by binding the Fc region of IgA antibodies, triggering phagocytosis, inflammatory mediator release, and antibody-dependent cellular cytotoxicity. FCAR plays significant roles in mucosal immunity and has been implicated in various pathological conditions including IgA nephropathy, inflammatory bowel disease, and certain autoimmune disorders. Dysregulation of FCAR signaling has also been associated with chronic inflammatory diseases and immune complex-mediated pathologies.
The reference antibody JJP-1212 has been utilized in immunological research to investigate FCAR expression patterns and functional mechanisms in immune responses. This biosimilar provides researchers with a reliable tool for studying FCAR-mediated immune processes, exploring therapeutic targets in IgA-related diseases, and investigating myeloid cell biology in both normal and disease contexts.
There are currently no reviews for this product.